Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio...

End-of-treatment results from STARTVerso 4 evaluating HIV/HCV co-infected patients will also be presented.

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Pivotal-Phase-3-Data-from-Boehringer-Ingelheim-Hep/ArticleNewsFeed/Article/detail/824484?ref=25